Clinical Pharmacology of an Atrasentan and Docetaxel Regimen in Men with Hormone-Refractory Prostate Cancer

PURPOSE: This study was conducted to evaluate potential pharmacokinetic interactions between docetaxel and atrasentan as part of a phase I/II clinical trial. METHODS: Patients with prostate cancer were treated with intravenous docetaxel (60-75 mg/m(2)) every three weeks and oral atrasentan (10 mg) d...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Younis, Islam R., George, Daniel J., McManus, Terence J., Hurwitz, Herbert, Creel, Patricia, Armstrong, Andrew J., Yu, Jing Jie, Bacon, Kristina, Hobbs, Gerald, Peer, Cody J., Petros, William P.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010098/
https://ncbi.nlm.nih.gov/pubmed/24619498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2432-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky